



## **Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference**

April 4, 2022

FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be presenting at the 21<sup>st</sup> Annual Needham Virtual Healthcare Conference on Monday, April 11 at 2:15 p.m. ET.

A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at <http://ir.ternspharma.com>. A replay of the webcast will be archived on Terns' website for 30 days following the presentation.

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH and obesity. Terns' pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- $\beta$  agonist, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

### **Contacts for Terns**

#### **Investors**

Justin Ng

[investors@ternspharma.com](mailto:investors@ternspharma.com)

#### **Media**

Jenna Urban

Berry & Company Public Relations

[media@ternspharma.com](mailto:media@ternspharma.com)